rs12678919 — LPL

LPL rs12678919 — The Lipid-Clearing Downstream Variant

Lipoprotein lipase (LPL¹¹ LPL
the enzyme anchored to capillary walls in muscle and adipose tissue that breaks down triglycerides carried in VLDL and chylomicrons, releasing free fatty acids for energy use or storage) is the central enzyme in plasma triglyceride clearance. The variant rs12678919 sits in a regulatory region roughly 19 kilobases downstream of the LPL gene body. It is an intergenic tag SNP that marks a haplotype block associated with altered LPL expression or activity — the precise functional variant within this block has not been identified, but the association with LPL biology is unambiguous across dozens of independent studies.

The G allele at this position — carried by roughly one in ten people globally — consistently associates with lower circulating triglycerides and higher HDL cholesterol. Carriers of one or two G copies have meaningfully better lipid profiles than non-carriers, and Mendelian randomization analyses support a causal relationship between this LPL-locus variation and reduced cardiovascular risk.

The Mechanism

LPL hydrolyzes triglycerides from chylomicrons²² chylomicrons
particles that carry dietary fat from the intestine to peripheral tissues after a meal and VLDL³³ VLDL
very low-density lipoprotein, the liver's primary vehicle for exporting endogenous triglycerides into the circulation. As LPL processes these particles, the excess phospholipids and apolipoproteins shed from the shrinking particles are transferred to HDL — which is why higher LPL activity simultaneously lowers TG and raises HDL. The rs12678919 G allele appears to tag variants that sustain or enhance this LPL-mediated clearance, producing the dual benefit seen in GWAS.

Because the precise regulatory mechanism is not yet resolved, the exact functional change is described as regulatory rather than missense. Several candidate mechanisms include altered transcription factor binding in enhancer elements downstream of the gene, modified mRNA stability, or haplotype-level effects through linkage with coding variants such as rs328 (S447X, the well-studied gain-of-function variant) and rs10096633.

The Evidence

The association of rs12678919 with triglycerides and HDL is among the most robustly replicated findings in lipid genetics. Teslovich et al. (Nature, 2010)⁴⁴ Teslovich et al. (Nature, 2010)
Teslovich TM et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707–713 analyzed over 100,000 individuals and found rs12678919-G associated with a 13.64 mg/dL reduction in triglycerides (p=2×10⁻¹¹⁵) and a 2.25 mg/dL increase in HDL cholesterol (p=1×10⁻⁹⁷). The GLGC 2013 meta-analysis⁵⁵ GLGC 2013 meta-analysis
Willer CJ et al. Discovery and refinement of loci associated with lipid levels. Nature Genetics 2013;45:1274–1283 in over 188,000 participants confirmed rs12678919 as the lead signal for the LPL locus, with even stronger p-values reaching 2×10⁻¹⁹⁹ for TG. Both the HDL and TG associations replicated across European, East Asian, South Asian, and African American populations.

The LPL locus variants — including rs12678919 — have been incorporated into Mendelian randomization studies demonstrating a causal relationship between LPL-driven TG reduction and lower coronary artery disease risk. Nine LPL- associated SNPs collectively show consistently protective effects on CAD when modeled as instruments for TG-lowering.

Practical Actions

Carriers of the G allele have a naturally favorable lipid signature from this locus. This does not override all dietary or metabolic influences, but the LPL machinery at this locus is operating more efficiently. For carriers: the saturated fat and refined carbohydrate thresholds that trigger triglyceride elevation are effectively wider — the clearance system is more robust.

For the AA genotype (the common baseline): the locus is not conferring extra TG-clearing capacity. Dietary saturated fat raises TG more easily, and postprandial lipemia is cleared less rapidly. Targeted interventions — specifically omega-3 fatty acids at therapeutic doses, which up-regulate LPL activity, and limiting refined carbohydrates that drive hepatic VLDL-TG production — address this directly. A fasting lipid panel every 2–3 years from age 35 is reasonable baseline monitoring.

Interactions

rs12678919 is in partial LD with several other LPL-region SNPs including rs328 (S447X, the gain-of-function coding variant), rs10096633, rs17482753, and rs10503669. Conditional analyses indicate these represent partially independent signals within the same locus. Carrying rs328 X allele on the same haplotype as the rs12678919 G allele may produce additive TG-lowering, though the degree of LD means these variants co-occur more often than not in European populations.

The LPL locus interacts functionally with APOC3 (rs2854116, rs2854117): apoC-III inhibits LPL activity, and high APOC3 expression can override the benefit of a favorable LPL haplotype. Carriers of rs12678919 AA who also carry TG-raising APOC3 variants may see attenuated benefit from dietary interventions targeting LPL.